IMT Header

Cambridge Healthtech Institute’s 3rd Annual
Immunomodulatory Therapeutic Antibodies for Cancer
Exploring the next generation of targets, indications and drug product formats for cancer immunotherapy
August 24-25


Recent regulatory approvals and a succession of favorable clinical data from the checkpoint inhibitor programs of major pharmas are now spearheading a new focus on immune system-modulating antibody therapeutics.  These results are now driving interest across academic and industry research into a next generation of checkpoint blockades and co-stimulatory factors, and the application of these to additional tumor types and in exciting new roles in combination treatment regimens.  For 2015, CHI’s Third Annual Immunomodulatory Therapeutic Antibodies for Cancer will explore developments in mainstream and emerging targets in this space, review progress in the application of immunotherapy for difficult to treat cancers and consider different concepts for developing multifunctional antibody immunotherapies.

Then, with this meeting as a foundation, the following ImVacS conference, Rational Combination Cancer Immunotherapy, will review strategies for combining immune-modulating antibodies with traditional and experimental therapeutics for improved clinical benefit to patients.

The organizers invite proposals for the conference that offer presentations of new data, new approaches and novel science from industry scientists or academic research groups working in late preclinical or clinical stage development of immunomodulatory antibody therapeutics.

Topics may include, but are not limited to: 

Major Targets  

  • Update from ASCO on PD-1 clinical progress and new indications
  • Clinical trials of anti-PD1/PDL1 combinations with other FDA-approved agents
  • Intellectual property review of major immunotherapy targets: Non composition of matter approaches to developing unique IP in cancer immunotherapy

Emerging Targets, Pathways and Mechanisms 

  • Endothelial cell regulation to improve T cell extravasation
  • Exosomes and regulation of the anti-tumor immune response
  • Immunomodulatory targets on TILs
  • Immunomodulatory targets on Tregs
  • Immunomodulatory targets on tumor cells 
  • Metabolomics and regulation of T-cell differentiation and the anti-tumor response
  • NK cells
  • Role of Innate Lymphoid Cells (ILCs)
  • Targeting the cancer mutanome
  • Targeting the tumor microenvironment

Emerging Indications  

  • Hematological malignancies
  • New and noteworthy solid tumor indications

Multifunctional Antibody Immunotherapies  

  • Bispecific/targeted immunotherapy combinations
  • Challenges in the development of bispecific antibodies for cancer immunotherapy
  • Dual antigen approaches to cancer immunotherapy
  • Fusion proteins

Preclinical Development of Immunomodulatory Antibodies  

  • Discovery biomarkers
  • Preclinical models of efficacy and toxicology
  • New humanized mouse models

Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract.  Remember to specify the conference that you are interested in and please provide your full contact information.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality conference program.  

If you are interested in presenting, please submit a speaking proposal for review.  Replies to proposals can take up to 8-12 weeks. We will notify you once the agenda has been finalized.

Deadline for submission is February 2, 2015. 

We welcome your comments, suggestions and speaker suggestions as we shape the 2015 program

For more details on the conference, please contact:
Kent Simmons
Conference Director
Cambridge Healthtech Institute
T: (+1) 207-869-9199
E: ksimmons@healthtech.com  

For exhibit & sponsorship opportunities, please contact:
Katelin Fitzgerald
Sr. Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5458
E: kfitzgerald@healthtech.com